ArKal grabs $17.5m for blood glucose monitor tech
This article was originally published in Clinica
Continuous blood glucose monitoring specialist ArKal Medical has raised $17.5m in a series B financing round led by Thomas McNerney & Partners. Delphi Ventures and MedVenture Associates, both existing shareholders in Fremont, California-based ArKal, also made significant contributions. ArKal, which is in stealth mode, said it will use the new funding to advance "the next stage of corporate and product milestones".
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.